Implantable Cardioverter-defibrillator Use in Structural Heart Disease: Narrowing the Playing Field.
作者信息
Ellis Christopher R
机构信息
Vanderbilt Heart and Vascular Institute, Nashville, TN, USA.
出版信息
J Innov Card Rhythm Manag. 2018 Feb 15;9(2):3033-3034. doi: 10.19102/icrm.2018.090207. eCollection 2018 Feb.
Abstract
摘要
相似文献
1
Implantable Cardioverter-defibrillator Use in Structural Heart Disease: Narrowing the Playing Field.植入式心脏复律除颤器在结构性心脏病中的应用：缩小范围
J Innov Card Rhythm Manag. 2018 Feb 15;9(2):3033-3034. doi: 10.19102/icrm.2018.090207. eCollection 2018 Feb.
2
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.植入式心脏复律除颤器治疗的风险分层：可穿戴式心脏除颤器的作用。
Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31.
3
Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.胸壁单极植入式心脏复律除颤器的多中心经验。主动除颤电极导线研究者。
J Am Coll Cardiol. 1996 Aug;28(2):400-10.
4
[Long-term outcome of pharmacological and nonpharmacological treatment for ventricular arrhythmias].[室性心律失常的药物和非药物治疗的长期结果]
J Cardiol. 2000 Mar;35 Suppl 1:75-84.
5
Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).大多数植入式心脏复律除颤器/心脏再同步治疗除颤器患者可行无诱导或有限电击测试：多中心ASSURE研究（心律失常单次电击除颤阈值测试与易损性上限：植入式心脏复律除颤器植入的风险降低评估）结果
Circulation. 2007 May 8;115(18):2382-9. doi: 10.1161/CIRCULATIONAHA.106.663112. Epub 2007 Apr 30.
6
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.肥厚型心肌病中的植入式心脏复律除颤器
Rev Port Cardiol. 2005 Mar;24(3):407-15.
7
Non-traditional implantable cardioverter-defibrillator configurations and insertion techniques: a review of contemporary options.非传统型植入式心脏复律除颤器的配置和插入技术：当代选择的回顾。
Europace. 2022 Feb 2;24(2):181-192. doi: 10.1093/europace/euab178.
8
Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy.无明显结构性心脏病患者的心室颤动：植入式心脏复律除颤器治疗的多中心经验
J Am Coll Cardiol. 1993 May;21(6):1406-12. doi: 10.1016/0735-1097(93)90317-t.
9
The impact of implantable cardioverter-defibrillators on mortality among patients on the waiting list for heart transplantation.
J Thorac Cardiovasc Surg. 1995 Aug;110(2):532-9. doi: 10.1016/S0022-5223(95)70251-2.
10
High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias.不明病因晕厥且可诱发出室性心律失常的患者中，植入式心律转复除颤器治疗的适宜性发生率较高。
J Am Coll Cardiol. 1997 Feb;29(2):370-5. doi: 10.1016/s0735-1097(96)00477-9.
本文引用的文献
1
Optimal Strategies for Mitigating Sudden Cardiac Death Risk in At-risk Patients with Structural Heart Disease.降低结构性心脏病高危患者心脏性猝死风险的优化策略
J Innov Card Rhythm Manag. 2018 Feb 15;9(2):3025-3032. doi: 10.19102/icrm.2018.090204. eCollection 2018 Feb.
2
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.非缺血性收缩性心力衰竭患者的除颤器植入
N Engl J Med. 2016 Sep 29;375(13):1221-30. doi: 10.1056/NEJMoa1608029. Epub 2016 Aug 27.
3
Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial.冠心病患者植入除颤器前稳定型室性心动过速的导管消融（VTACH）：一项多中心随机对照试验。
Lancet. 2010 Jan 2;375(9708):31-40. doi: 10.1016/S0140-6736(09)61755-4.
4
Prophylactic catheter ablation for the prevention of defibrillator therapy.预防性导管消融术用于预防除颤器治疗。
N Engl J Med. 2007 Dec 27;357(26):2657-65. doi: 10.1056/NEJMoa065457.
5
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.急性心肌梗死后植入式心脏复律除颤器的预防性应用。
N Engl J Med. 2004 Dec 9;351(24):2481-8. doi: 10.1056/NEJMoa041489.
Zotero 插件